- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03080948
Risk Stratification Among Individuals Who Have Many Moles on Their Skin
April 1, 2024 updated by: Memorial Sloan Kettering Cancer Center
Cutaneous Melanoma Risk Stratification of Individuals With a High-Risk Nevus Phenotype
The investigators are doing this study to improve our ability to identify which people with many moles on their skin are most likely to develop skin melanoma.
The investigators hope to identify features of moles that are associated with melanoma risk.
The investigators hope to use this information to customize and tailor melanoma screening to the individual patient based on a better estimate of their individual risk.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
73
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge
-
-
New York
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester
-
Hauppauge, New York, United States, 11788
- Memorial Sloan Kettering Cancer Center Hauppauge
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All patients in the Melanoma Screening and Surveillance Program (MSSP).
Description
Inclusion Criteria:
- Patients ≥ 18 years of age
- High-risk nevus phenotype (≥ 50 nevi (≥ 2mm in size) and ≥ 1 atypical nevus)
- First presented to MSKCC for cutaneous melanoma-related care on or after April 2016
- Cases: diagnoses of unequivocal invasive cutaneous melanomas (AJCC Stages I-IV) confirmed by MSKCC pathology on or after April 2016
- Cases: completion of surgical treatment of primary melanoma
- Ability to sign or verbally consent to the informed consent
Exclusion Criteria:
- Controls: Histopathologically borderline melanocytic tumors for which melanoma could not be excluded or that were treated as possible melanomas.
- Known germline high-penetrance melanoma predisposition mutation (that is, CDKN2A, CDK4, and BAP1)
- Cases: history of invasive cutaneous melanoma (AJCC Stages I-IV) not confirmed by MSKCC pathology
- History of acrolentiginous type of cutaneous melanoma or history of mucosal melanoma
- Cases and controls: prior administration of systemic medications known to modify nevus phenotype, including but not limited to: MEK inhibitors (trametinib, cobimetinib, etc.), BRAF inhibitors (vemurafenib, dabrafenib, etc.), and immunotherapy (pembrolizumab, nivolumab, atezolizumab, ipilimumab, etc.). Controls: history of Stage 0-IV melanoma confirmed by MSKCC pathology
- History of limb amputation or other condition (e.g., tattoos, burns) per investigator discretion that would modify nevus phenotype
- Physical inability to undergo total body photography or reflectance confocal microscopy imaging (that is, remain relatively still for durations of 3-5 minutes)
- Known hypersensitivity to adhesive rings used for reflectance confocal microscopy
- Inability to give informed consent
- Have skin afflicted with anther skin condition (for example, psoriasis) that would affect ability to characterize nevus phenotype (per investigator discretion)
- Familial cutaneous melanoma history (families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma or pancreatic cancer among first- or second-degree relatives on the same side of the family). We will confirm melanoma family history via medical record documentation, whenever possible, as recommended by previous studies that disproved about half of the reported family histories of melanoma among first-degree relatives in case-control studies.
- Age 70 or above
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
History of Melanoma (cases)
Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification.
In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes.
The evaluations needed for this study protocol will be primarily performed during routine clinical care.
|
Research assessments as part of this protocol will be scheduled during routine clinic visits
Germline DNA analysis
|
No Melanoma History (controls)
Participants at high-risk for melanoma (that is, those having many nevi and morphologically atypical nevi) who either have a history of invasive melanoma (cases) or do not have a history of melanoma (controls) and will perform comprehensive total body imaging of their moles in order to identify phenotypic markers of melanoma risk that aid in melanoma risk stratification.
In addition, we will investigate histopathologic and molecular features of moles that are associated with melanoma risk and with melanoma subtypes.
The evaluations needed for this study protocol will be primarily performed during routine clinical care.
|
Research assessments as part of this protocol will be scheduled during routine clinic visits
Germline DNA analysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of patients having specific dermoscopic patterns
Time Frame: 2 years
|
For each person, the proportions of their nevi having specific dermoscopic patterns will be calculated.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Allan Halpern, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2017
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
March 10, 2017
First Submitted That Met QC Criteria
March 10, 2017
First Posted (Actual)
March 15, 2017
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-083
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-Risk Nevus Phenotype
-
Xijing HospitalRecruitingHigh-Risk Percutaneous Coronary Intervention (High-risk PCI) | Left Ventricular Assist DevicesChina
-
Array BioPharmaCompletedAML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDSUnited States, Australia, Italy, Spain, France, Switzerland, United Kingdom
-
George Washington UniversityUniversity of North Carolina, Chapel Hill; Aga Khan University; Kenya Medical... and other collaboratorsRecruitingPregnancy, High RiskPakistan, Ghana, Kenya, India, Zambia
-
George Washington UniversityRecruitingPregnancy, High RiskPakistan, Kenya, Zambia
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia
-
University of AarhusCopenhagen University Hospital, HvidovreCompletedAn Adapted Mindfulness-based Stress Reduction Program for Psycho-socially Vulnerable Pregnant Women.Pregnancy, High RiskDenmark
-
Ain Shams UniversityCompletedHigh Risk PregnancyEgypt
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedHigh-risk MedicationsUnited States
-
University Hospital, LilleCompletedPregnancy, High RiskFrance
-
University of British ColumbiaNational Institutes of Health (NIH)Completed
Clinical Trials on survey
-
Johns Hopkins Bloomberg School of Public HealthPontificia Universidad JaverianaCompletedNoncommunicable Diseases | Surveys and QuestionnairesColombia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Ohio State UniversityWithdrawnMedicare Part DUnited States
-
Johns Hopkins Bloomberg School of Public HealthIfakara Health InstituteCompletedNoncommunicable Diseases | Surveys and QuestionnairesTanzania
-
Memorial Sloan Kettering Cancer CenterCompletedInpatients With Limited English ProficiencyUnited States
-
Lawson Health Research InstituteCompletedEvaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation ParticipationMyocardial Infarction | Unstable Angina | Coronary Angioplasty | Coronary Artery Bypass SurgeryCanada
-
University GhentCompletedStroke | Upper Extremity Paresis | Survey
-
Assistance Publique - Hôpitaux de ParisUniversité de Cergy PontoiseCompleted
-
Weill Medical College of Cornell UniversityBoston Children's Hospital; Brigham and Women's Hospital; The Commonwealth FundCompletedPediatric ALLUnited States